ARS Pharmaceuticals: Investors May Lead Securities Fraud Lawsuit

Rosen Law Firm is reminding purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) of the opportunity to serve as lead plaintiff in a securities fraud class action lawsuit. The lawsuit concerns allegations that ARS Pharmaceuticals made materially false or misleading statements during the class period.

Investors who purchased SPRY securities between March 9, 2026, and June 24, 2026, inclusive, may be eligible to serve as lead plaintiff. The firm is investigating potential violations of federal securities laws.

Shareholders who wish to learn more about their rights and potential recovery are encouraged to contact Rosen Law Firm. The deadline to seek appointment as lead plaintiff is October 5, 2026.

Rosen Law Firm has extensive experience in prosecuting securities class actions on behalf of investors. The firm is dedicated to recovering losses for investors who have been harmed by corporate misconduct.